ITEM VIEW

Accelerating clinical evaluation of repurposed combination therapies for COVID-19

dc.contributor.authorRayner, Craig R.en_ZA
dc.contributor.authorDron, Louisen_ZA
dc.contributor.authorPark, Jay J. H.en_ZA
dc.contributor.authorDecloedt, Eric H.en_ZA
dc.contributor.authorCotton, Mark F.en_ZA
dc.contributor.authorNiranjan, Visen_ZA
dc.contributor.authorSmith, Patrick F.en_ZA
dc.contributor.authorDodds, Michael G.en_ZA
dc.contributor.authorBrown, Franen_ZA
dc.contributor.authorReis, Gilmaren_ZA
dc.contributor.authorWesche, Daviden_ZA
dc.contributor.authorMills, Edward J.en_ZA
dc.date.accessioned2020-09-02T08:39:24Z
dc.date.available2020-09-02T08:39:24Z
dc.date.issued2020-08-21
dc.identifier.citationRayner, C. R. et al. 2020. Accelerating clinical evaluation of repurposed combination therapies for COVID-19. American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-0995.
dc.identifier.issn1476-1645 (online)
dc.identifier.otherdoi:10.4269/ajtmh.20-0995
dc.identifier.urihttp://hdl.handle.net/10019.1/108777
dc.descriptionCITATION: Rayner, C. R. et al. 2020. Accelerating clinical evaluation of repurposed combination therapies for COVID-19. American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-0995.
dc.descriptionThe original publication is available at https://www.ajtmh.org
dc.description.abstractAs the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for accelerated development is the evaluation of drug combinations in the absence of prior monotherapy data. This approach is appealing for a number of reasons. First, combining two or more drugs with related or complementary therapeutic effects permits a multipronged approach addressing the variable pathways of the disease. Second, if an individual component of a combination offers a therapeutic effect, then in the absence of antagonism, a trial of combination therapy should still detect individual efficacy. Third, this strategy is time saving. Rather than taking a stepwise approach to evaluating monotherapies, this strategy begins with testing all relevant therapeutic options. Finally, given the severity of the current pandemic and the absence of treatment options, the likelihood of detecting a treatment effect with combination therapy maintains scientific enthusiasm for evaluating repurposed treatments. Antiviral combination selection can be facilitated by insights regarding SARS-CoV-2 pathophysiology and cell cycle dynamics, supported by infectious disease and clinical pharmacology expert advice. We describe a clinical evaluation strategy using adaptive combination platform trials to rapidly test combination therapies to treat COVID-19.en_ZA
dc.description.urihttps://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0995
dc.format.extent3 pages
dc.language.isoen_ZAen_ZA
dc.publisherAmerican Society of Tropical Medicine and Hygiene
dc.subjectCOVID-19 (Disease)en_ZA
dc.titleAccelerating clinical evaluation of repurposed combination therapies for COVID-19en_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyright


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW